PERIPHERAL T CELL LYMPHOMA
Clinical trials for PERIPHERAL T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test new drug cocktail in fight against tough blood cancers
Disease control CompletedThis early-stage study aimed to find the safest dose of a new four-drug combination (romidepsin plus GDP) for patients with two types of aggressive lymphoma that had returned after prior treatment. The main goal was to determine how much of the new drug could be added without cau…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Experimental drug targets Cancer's internal brakes in patients out of options
Disease control CompletedThis early-stage trial tested a new drug called ALRN-6924, alone or with another cancer drug, in 142 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors …
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope for Tough-to-Treat blood cancer patients
Disease control CompletedThis study tested whether adding the drug brentuximab vedotin to standard chemotherapy (CHP) works for people newly diagnosed with certain aggressive types of peripheral T-cell lymphoma (PTCL) who have low levels of a specific protein called CD30. The trial involved 82 participan…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug combo tested in High-Stakes fight against rare blood cancers
Disease control CompletedThis study tested whether adding the drug romidepsin to a stem cell transplant could better control several aggressive types of T-cell blood cancers. Researchers gave romidepsin before and after the transplant to 23 patients to find the safest dose and see if it helped. The main …
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Immune-Boosting drug tested to stop aggressive lymphoma from coming back
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab after a patient's own stem cell transplant could help keep certain aggressive lymphomas from returning. It involved 82 adults with Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma that had co…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New pill tested for Tough-to-Treat blood cancers
Disease control CompletedThis first-in-human study tested a new oral drug called BR101801 in adults with advanced blood cancers that had returned or stopped responding to other treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early s…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New drug cocktail tested for rare, aggressive cancers
Disease control CompletedThis early-stage study tested whether a combination of four existing drugs could be safely given to adults with rare T-cell cancers that had returned or stopped responding to standard treatments. The main goal was to find the safest dose and understand the side effects. Researche…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New oral drug tested for aggressive blood cancer that has returned
Disease control CompletedThis study tested an experimental oral medication called AZD4205 in adults whose peripheral T-cell lymphoma, a type of blood cancer, had returned or did not respond to prior treatment. The main goal was to see if the drug could shrink tumors and how safe it was for patients. Rese…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC